Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Judge partly vacates convictions of opioid maker Insys' founder, executives

Stock MarketsNov 26, 2019 09:05PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. John Kapoor arrives at the federal courthouse in Boston

By Nate Raymond

BOSTON (Reuters) - A federal judge on Tuesday partially overturned the convictions of Insys Therapeutics Inc's founder and three former executives accused of bribing doctors to prescribe an addictive opioid, but declined to disturb the remainder of the jury's verdict.

U.S. District Judge Allison Burroughs in Boston ruled the evidence prosecutors presented at trial did not support finding that John Kapoor and the others intended for doctors to prescribe the drug, Subsys, to patients who did not need it.

The ruling could impact the eventual sentence received by Kapoor, the highest-ranking pharmaceutical executive to be convicted in a case tied to the deadly U.S. opioid addiction epidemic.

Chandler, Arizona-based Insys filed for bankruptcy in June days after striking a $225 million settlement with the U.S. Justice Department.

A federal jury found Kapoor, its onetime chairman, guilty in May of running a wide-ranging scheme to bribe doctors nationwide by retaining them to act as speakers at sham events ostensibly meant to educate clinicians about its fentanyl spray, Subsys.

But in her 85-page ruling, Burroughs said prosecutors failed to establish that Kapoor and his co-defendants intended for doctors to abdicate their duties to their patients and prescribed them Subsys for non-legitimate medical uses.

"Even though the evidence could be readily understood as proving that defendants did not care whether patients needed the drug, that still is not enough to prove the requisite intent," Burroughs wrote.

As a result, she vacated the convictions of Kapoor and three former executives, Richard Simon, Sunrise Lee and Joseph Rowan, for conspiring to illegally distribute a controlled substance and commit honest services fraud.

Those were some of the so-called predicate acts underlying their racketeering conspiracy conviction. She declined to overturn the related mail fraud and wire fraud convictions of those four and another former executive, Michael Gurry.

Burroughs said the evidence on those counts supported finding they carried out a scheme to bribe doctors and defraud insurers into paying for Subsys, which was approved only for treating pain in cancer patients.

Beth Wilkinson, Kapoor's lawyer, in a statement said: "We have always believed that the government brought charges it could not sustain."

She and other defense lawyers in court papers had claimed the illegal drug distribution charge if sustained could have resulted in longer prison sentences and Kapoor being sent to a prison reserved for "leaders and organizers in the drug-dealing world."

He and the others face sentencing in January.

Judge partly vacates convictions of opioid maker Insys' founder, executives
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email